

AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-305-671-0200.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Antiparkinson Agents

<input type="checkbox"/> Inbrija™ (levodopa inhalation powder)	<input type="checkbox"/> Nourianz™ (istradefylline)
<input type="checkbox"/> Ongentys® (opicapone)	<input type="checkbox"/> tolcapone (Tasmar)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member AvMed #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight: _____ Date: _____

RECOMMENDED DOSAGE:

- **Inbrija™:** Oral inhalation: 84 mg up to 5 times daily as needed when symptoms of an OFF period return. Maximum quantity limit: 84 mg/dose and 420 mg/day.
- **Nourianz™:** Oral: 20 mg once daily; may further increase dose based on response and tolerability to a maximum dose of 40 mg once daily. Maximum quantity limit: 30 tablets /30 days
- **Ongentys®:** Oral: 50 mg once daily at bedtime. Maximum quantity limit: 30 tablets/30 days.
- **tolcapone (Tasmar):** Oral: Initial: 100 mg 3 times daily always as an adjunct to levodopa/carbidopa; may increase as tolerated to 200 mg 3 times daily. Maximum quantity limit: 180 tablets/30days

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization Approval: 6 months

- Member must be 18 years of age or older

AND

- Medication must be prescribed by, or in consultation with a neurologist

AND

- Member must have a confirmed diagnosis of Parkinson's disease in an individual who is having intermittent OFF episodes while on continuous carbidopa/levodopa therapy and all of the following criteria has been met: **(must submit chart notes)**
 - Provider has made adjustments to adjust the carbidopa/levodopa's dose in order to manage symptoms without success

AND

- Member is receiving concurrent therapy with carbidopa/levodopa **within the past 30 days** AND the requested medication will be used in combination with continuous carbidopa/levodopa treatment

AND

- For ALL Antiparkinson Agents**, member is currently not taking or has not recently (within 2 weeks) taken a nonselective MAO inhibitor such as Nardil[®] (phenelzine), Parnate[®] (tranylcypromine), or Marplan[®] (isocarboxazid)

For tolcapone (Tasmar). Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- Member must have documentation of trial and failure of **TWO (2)** of the following:
 - COMT inhibitor: generic entacapone

AND

- Dopamine agonist: ropinirole/ropinirole ER, pramipexole/pramipexole ER; **OR**
- Monoamine oxidase type B inhibitors: rasagiline; **OR**
- Ongentys[®] (opicapone) requires prior authorization; **OR**

AND

- Provider attestation to monitor for liver failure/hepatic dysfunction and should discontinue tolcapone if ALT/AST levels exceed 2 times the upper limit of normal

(Continued on next page)

For Ongentys®. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- Member must have documentation of trial and failure of **TWO (2)** of the following:
 - COMT inhibitor: generic entacapone

AND

- Dopamine agonist: ropinirole/ropinirole ER, pramipexole/pramipexole ER; **OR**
- Monoamine oxidase type B inhibitors: rasagiline; **OR**

AND

- Member does not have a history of pheochromocytoma, paraganglioma, or other catecholamine-secreting neoplasms

For Inbrija® or Nourianz®. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- Member must have documentation of trial and failure of **TWO (2)** of the following:

- Monoamine oxidase type B inhibitors: rasagiline; **OR**
- Dopamine agonist: ropinirole/ropinirole ER, pramipexole/pramipexole ER; **OR**
- COMT inhibitor: generic entacapone, Ongentys® (requires prior authorization), tolcapone (requires prior authorization)

AND

- Member does not have a history of asthma, COPD, or other chronic underlying lung disease (**for Inbrija™ only**)

Reauthorization Approval: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- Member must continue to meet initial approval criteria

AND

- Member has a documented positive clinical response to treatment (defined as: improvement and stabilization of “off episodes” associated with Parkinson’s disease)

AND

- Medication is used in combination with carbidopa/levodopa (**must have pharmacy paid claims**)

(Continued on next page)

AND

- ❑ Member must be absent of unacceptable toxicity from therapy

Medication being provided by Specialty Pharmacy - PropriumRx

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.